Posts Tagged ‘Depression Research’

SAMe SUPPLEMENTS EASE DEPRESSION IN PATIENTS WHO DON’T RESPOND TO CONVENTIONAL ANTI-DEPRESSANT DRUGS

Monday, September 6th, 2010

SAMe stands for S-adenosyl methionine. It is a naturally occurring molecule first discovered in Italy in 1952 by G.L. Cantoni. Most of it is produced and consumed in the human liver. It is involved in over 40 metabolic reactions including biosynthesis of certain nucleic acids and proteins. A company called Pharmavite makes and sells SAMe as a dietary (non-drug) supplement for depression help.

Approximately one-third of depressed patients do not respond to conventional anti-depressant drugs like Prozac and Zoloft. These drugs work by blocking the re-uptake of serotonin from the synapses after it is released, so more of it is available for neuro-transmission. They are called SSRIs or selective serotonin reuptake inhibitors. In order to explore whether SAMe supplementation would help depressed patients whose depression was not improving by taking an SSRI medication, investigators at Harvard Medical School and Massachusetts General Hospital in Boston recruited a group of 73 adults with depression who were resistant to SSRIs.

According to lead author, psychiatrist George I. Papakostas of Mass. General, all of the patients were kept on their regular medication for the six week study. However, 39 were randomly assigned to take SAMe and 34 received a placebo. Neither the investigators not the patients knew who was getting SAMe and who was getting placebo. This sort of study is called a randomized, double blind, placebo controlled study.

At the end of the study 36% of the patients taking a combination of anti-depressant and SAMe showed improvement compared to just 18% of those taking anti-depressant and placebo. And 26% of the patients in the SAMe group achieved complete remission of symptoms, compared to 12% in the placebo group.

Dr. Papakostas published the results of the study in American Journal of Psychiatry (in the July 2010 online version and the August 2010 hard copy). He said that SAMe appears to be a valuable adjunctive therapy to regular anti-depressants for some patients, but larger studies are required to replicate his findings. Dr. Papakostas speculated that SAMe helps by facilitating the biosynthesis of serotonin, which is different from simply blocking its reuptake.

If you’re taking a conventional anti-depressant drug which works by blocking re-uptake of a neurotransmitter and you’re not experiencing improvement, then you should talk to your physician or psychiatrist about this study. In an editorial accompanying Dr. Papakostas’ study psychiatrist Craig Nelson of the UCSF Medical Center said that SAMe shows promise for helping patients with treatment-resistant depression, but is not covered by most insurance companies. The cost of a one month supply of SAMe from Pharmavite is about $143.

HIGH FAT DIET IMPAIRS DOPAMINE SIGNALING IN THE BRAIN AND REDUCES MOTIVATION

Wednesday, August 4th, 2010

On the level of neurotransmitters, the human motivation to undertake action comes largely from the transmission (signaling) of dopamine. In July 2010 neuroscientist Mitchell F. Roitman, Ph.D., an Assistant Professor of Psychology at the University of Illinois in Chicago, announced the results of his research into the effect of a high fat diet on dopamine signaling in the brains of rats. He plans to publish his research in a prestigious journal within the next month or so.

Dr. Roitman fed one group of rats a high fat, high cholesterol diet and another group a normal diet. Using a specialized machine which measures dopamine production and re-uptake in the brains of living rats, he found that the rats fed a high fat diet produced significantly less dopamine than the control group. Because this created a shortage of dopamine in the synaptic space between the brain cells of the high-fat diet rats, the amount of dopamine re-uptake by their brain cells decreased to preserve what little dopamine was available. In the rats on a high fat diet, less brain dopamine caused decreased dopamine signaling with a decrease in behavioral motivation.

Parkinson’s patients (who suffer from decreased dopamine) are able to speak or move once they get going, but have difficulty initiating activity. In human beings dopamine shortage is associated with decreased motivation, passivity and depression. A number of drug companies are working right now to develop an anti-depressant which would reverse depression by increasing dopamine transmission.

We already know that a high fat diet contributes to diabetes, high blood pressure, heart attacks and strokes, all of which impair brain function. Dr. Roitman’s work is  important, because it shows one new mechanism by which a high fat diet impairs brain function, and adds to the reasons we already have to reduce our consumption of unhealthy fat. Dr. Roitman said his work puts questions marks around our cultural stereotype that obese people are lazy. It could be that the extra fat in their diet actually saps their motivation to move and exercise by impairing dopamine signaling in their brains.

The take home message is that it’s high time to decrease your daily consumption of unhealthy fat from refined and processed foods containing lots of sugar, high fructose corn syrup and partially hydrogenated fat. When you consume fat do your best to eat healthy fats like Omega 3s from cold water fish, nuts, nut butters, and seeds, and oils like extra virgin olive oil, flax oil, avocado oil, walnut oil, coconut oil or sesame seed oil. Keep your brain primed with enough dopamine to initiate the activities that keep you healthy and happy.

DEPRESSED PEOPLE ARE LITERALLY UNABLE TO SEE SHADE OF GRAY

Friday, July 30th, 2010

It has often been said that major depression is a condition of extremes, leaving the depressed person thinking only in terms of worst case scenarios, blaming himself for whatever goes wrong in his life, refusing to allow himself to experience pleasure and refusing to give himself credit for any positive accomplishment. Non-depressed people moderate their vision of themselves and the world around them. They see the world as good and the bad. They can experience pleasure as well as pain. They sometimes blame themselves and sometimes blame others. They alternate between hope and fear. In a figurative sense depressed people are unable to see shades of gray while non-depressed people can.

We have just learned that depressed people are literally much less able than non-depressed people to see shades of gray. In the July 15, 2010, issue of Biological Psychiatry, a group of researchers led by Emanuel Bubl of the Albert-Ludwigs-University of Freiburg published their study on the use of pattern electroretinogram assessment (PERG) on the eyes of depressed and non-depressed people. An electroretinogram is a machine which measures how the retina responds to visual contrast. Dr. Bubl wanted to find out if depressed patients had reduced sensitivity to contrast perception.

His group recruited and studied forty patients with a diagnosis of major depression (20 with and 20 without medication) and 40 matched healthy subjects. They recorded visual PERGs from both eyes of all study participants. Unmedicated and medicated depressed patients displayed dramatically lower retinal contrast perception, meaning they were much less able to detect shades of gray. The researchers found a strong and significant correlation between contrast perception and severity of depression. Computerized analysis revealed a specificity of 92.5% and a sensitivity of 77.5% for classifying the participants correctly. Because PERG recordings do not depend on subjective ratings by an optometrist, this decrement in the ability of a person’s retina to detect shades of gray is a marker or objective correlate of major depression which can be used for diagnostic purposes.

At this point we do not know why the retinas of people with major depression are so much less able to appreciate visual contrast between the shades of gray that lie between pure black and white. Perhaps neuro-ophthalmologists and neuro-psychiatrists will be able to answer this question in the future. Meanwhile it is a very intriguing piece of data which joins together our visual-psychological metaphor and our medical-ophthalmological understanding of depressed people as being unable to appreciate shades of gray.

NEW DISCOVERY IN RATS EXPLAINS HIGHER RATES OF ANXIETY AND DEPRESSION IN WOMEN BASED ON BRAIN DIFFERENCES

Thursday, June 24th, 2010
Epidemiologists know that women experience anxiety disorders three times as much as men and depression twice as much as men. In the past psychologists tried to account for this based on socialization. They noted that women are more open to talking about their feelings than men, and thus more likely to be diagnosed with a mood disorder than men. Before the women’s liberation movement, women were largely denied the right to work and were kept at home as housewives and mothers without the opportunity to engage their talents and leadership abilities. For many women this was an understandable source of frustration, grief, anger and depression. The expression “mother’s little helper” coined by the Rolling Stones in a song in 1966 referred to abuse of prescription drugs to get bored moms through their day.
After women changed our culture and got the right to work they took on the double burden of working and being the primary provider of childcare and housework. This occurred because many men were unwilling to take on more of the childcare and housework once their wives became employed. The double burden on women became a source of stress, fatigue and resentment towards their husbands. Psychologists have also noted that women are more subject to child abuse than men while growing up and this could explain their higher rates of PTSD.
While there may be some validity to these explanations, we now have a brain-based explanation of gender based differences in the rate of mood disorders thanks to research by behavioral neuroscientist Rita J. Valentino, Ph.D. and her research associate Debra A. Bangasser, Ph.D. In the June 15, 2010 issue of Molecular Psychiatry they reported the findings of their research on how the brains of male and female rats responded to stress. To tease out gender based differences they had rats undergo a swim stress test. After the test they found two differences related to CRF.
CRF or corticotropin releasing factor is a neuropeptide shared by rats and humans which is produced by the hypothalamus in response to stress. CRF signals the pituitary gland to secrete ACTH (adrenocorticotropic hormone) into the bloodstream. ACTH binds to the adrenal glands and signals them to produce the stress hormones adrenalin and cortisol which kicks off the fight-flight response. These hormones increase heart rate, respiratory rate and blood pressure. They dilate the pupils, make your hairs stand on end and cause dry mouth. They make people feel jittery, nervous and over-excited in an unpleasant way. In healthy animals and people CRF is secreted episodically, briefly and only when the organism is stressed. Anxious individuals secrete CRF chronically and chronic secretion of CRF (with chronically high levels of cortisol in the blood) causes depression.
The researchers found two differences in the brains of female and male rats. In the female rats the brain receptors for CRF bound more tightly to the cell signaling protein than the receptors in the male rat brains. This  boosted cellular signaling of CRF in the female rat, making it more sensitive to lower levels of CRF. Furthermore, as CRF was released and the supply of CRF built up, the brains of male rats decreased the number of CRF receptors in the area of the brain called the locus ceruleus making male rats less sensitive to and less responsive to higher levels of CRF. This adaptive process which is called internalization did not occur in the female rat brains because a protein important for internalization (Beta-arrestin2) did not bind to CRF receptors. Compromised internalization makes female rats less able to resist the effects of higher levels of CRF. The researchers concluded that enhanced signaling makes female rats more sensitive to low levels of CRF and compromised internalization makes them less adaptable to higher levels of CRF.
Dr. Valentino said it is not yet known if these gender-based differences in the stress response of rats hold true for humans, but if they do, this would help account for the higher vulnerability of women to develop stress-based pathology. Since many similarities exist between the brains of rats and people, this could well be the case. Dr. Valentino also noted that past research on stress had used male rats and did not focus on gender based differences in how male and female rats responded to stress, which is why this discovery too so long to be made.
Even though women have much higher rates of anxiety and depression than men, men are four times more likely to commit suicide consequent to living with those problems. Why is that? Psychologists say it’s because women are more able to disclose their emotional pain, talk about their feelings, seek support from other women and get that support. This is not just a cultural phenomenon but aligns with the strong tend-and-befriend response in women produced by their much higher levels of the hormone oxytocin. The irony is that although women may be hormonally saddled with higher rates of mood disorders, they are better able than men to deal with those disorders and overcome them, in part because of the hormone oxytocin.
Thanks to this research paper more research will start coming out in the future to elucidate these differences, and this research could pave the way for new drugs to treat women’s mood disorders which takes cellular and molecular brain differences into account.

MEDITATION HELPS REDUCE PAIN UNPLEASANTNESS IN PEOPLE WITH CHRONIC PAIN WHO SUFFER FROM DEPRESSION

Friday, June 11th, 2010
Chronic pain and depression re-enforce each other. Chronic pain that arises initially from injury or disease can trigger depression. The depression alters the experience of pain. It sensitizes the suffer to pain, augmenting both his sensory perception of pain and darkening his cognitive interpretation of pain. When a depressed person has a flare up of pain, he is more likely to feel victimized and overwhelmed and become trapped in worst case scenario thoughts like “oh no, it’s back again, this pain will never leave me alone.”
Chantal Berna, M.D., a doctoral student in psychiatry at the University of Oxford, has been studying the interaction of pain and depression using psychological testing and fMRI brain scans. In a recent study (published in the June 1, 2010 issue of Biological Psychiatry) Dr. Berna subjected two groups of ten healthy people to a painful heat stimulus, a control group and a group made sad by negative thoughts and depressing music. The sad mood group found the pain sensations more unpleasant than the control group. Depression, she said, is not simply a consequence of pain, but something which exacerbates pain, making it worse than it would be for someone in a neutral mood.
What is the underlying neural mechanism? Using a brain scanner Dr. Berna discovered that after being subjected to the painful heat stimulus the group with sad mood had increased activation in areas of the brain which regulate emotions. The participants who reported the largest increase in pain unpleasantness after the sad mood induction showed greater inferior frontal gyrus and amygdala activation. The amygdala is the brain’s fear alarm. When it reacts to a perceived survival threat it triggers the sympathetic nervous system into fight-flight mode leading to secretion of the stress hormones adrenalin and cortisol which make people jittery, anxious and nervous. Dr. Berna concluded that sad mood affects the emotional parts of the brain in such as a way as to enhance our emotional response to pain.
Lawyers, like all other occupational groups, have chronic pain conditions such as bad backs, migraines and the like. A depressed lawyer is going to have a stronger, more negative emotional response to his pain flare ups, and find his pain much more unpleasant than a non-depressed lawyer. When pain becomes too unpleasant it restricts work and home activities and dramatically reduces quality of life. So what can a depressed lawyer do to control his pain?
There are many scholarly articles, books and tapes available which teach meditation techniques to help people manage their brain by changing their cognitive and emotional response to pain. Jon Kabat-Zinn has an audio CD called Mindfulness Meditation for Pain Relief. Jackie Gardner-Nix has a book called The Mindfulness Solution to Pain. And, Vidyamala Burch has a book and CD called Living Well with Pain and Illness. Kristin Neff’s website www.self-compassion.org has guided meditations that can help you too. A wise person once said that while pain is unavoidable suffering is optional. Using these excellent resources you stand a good chance of reducing the unpleasantness of your pain and increasing your life quality and your capacity for activity.

EASE OF ANTIDEPRESSANT PILL USE CAN BE A TRAP

Saturday, June 5th, 2010

On June 1, 2010, Consumer Reports published data showing that Americans  prefer antidepressant pills to talk therapy and that 80% of Americans diagnosed with depression are taking drugs for depression, mainly the SSRIs like Prozac, Zoloft, Celexa or Lexapro. The August 2009 issue of Archives of General Psychiatry reported that the number of people taking prescription medication for depression in the U.S. doubled during the past decade. Between 1996 and 2005, the rate of antidepressant medication use  increased from 5.84% to 10.12% or from an estimated 13.3 million to 27 million individuals. Anti-depressants are now the most commonly prescribed drug in America.

The Consumer Reports survey of 1,500 people published on June, 1, 2010, showed that talk therapy with any kind of therapist (be it a psychiatrist, psychologist or social worker) for seven or more visits had the same efficacy in resolving symptoms as taking pills. Plenty of research data which was not mentioned the Consumer Reports article exists to show that talk therapy, meditation, exercise and other modalities used to treat depression physically change the brain in ways that reduce depression.

Antidepressant drugs only work well for about one-third of the people who take them. One third of the people who try them get only partial relief and one third gets no relief at all. Antidepressants are expensive. They cause short term side effects like nausea and headaches and long term side effects like weight gain, loss of sexual interest, delayed orgasm and blunting of personality. So why the lopsided preference for drugs over talk therapy? There are several reasons.

First the ease and convenience of taking a pill over scheduling appointments with a therapist, driving to and from his office, parking, and having to leave work or other activities for the visit. Second, Americans love pills. We take an astronomic number of medicines and supplements in pill form, when we would be better off exercising more and eating whole foods like fresh fruits and vegetables. Third, going to a therapist means working on your issues, confronting some painful truths, taking the risk of changing your behavior, and facing stigma from ignorant people who think seeing a therapist is a sign of being crazy, being too weak to handle your problems, or both.

Working with a therapist can be hard to do if you grew up in a home where people never spoke about or faced their emotional pain. It can be hard to do if you’re under a lot of stress, your immediate goal is survival and you worry that rocking the boat with therapy might cause you to capsize. Sometimes people are reluctant to go because they’ve heard bad stories about therapists or they don’t understand what happens in therapy and how therapists can benefit them.

Anti-depressants are strongly indicated when a patient is so severely depressed as to be suicidal or unable to function at work and home. With patients who have mild to moderate depression anti-depressant treatment certainly has its place. Such treatment can lift the patient’s mood, decrease irritability, help him sleep and facilitate positive re-engagement with colleagues and family. It can also put him in the frame of mind where he is better able to work with a therapist, because he is no longer seeing himself as a hopeless failure with no chance at self-improvement. On the other hand skipping therapy entirely and relying solely on anti-depressants is not a well conceived plan.

Psychiatrist Bruce Levine, M.D., author of Surviving America’s Depression Epidemic, says that many modern psychiatrists are not healers but technicians who make a DSM-IV diagnosis and then prescribe a pill for it, the same way that an auto mechanic would check the oil and then pour in a few quarts if it was low. He correctly points out that depression is a form of psychological shut-down or emotional numbing in response to intense emotional pain. Dr. Levine also says quite correctly that a good therapist will see his patient as a whole person, that he will have great curiosity as to what has caused his patient to have so much emotional pain and that he will work with his patient in a caring, humane and dignified manner to help him resolve his own inner conflicts.

Dr. Levine sees emotional pain not as an individual abnormality, but as part of the universal human experience. He sees it as a signal that how one is living one’s life is psychologically harmful and a cue to explore the origin of that pain to heal one’s emotional wounds. He worries people are using anti-depressants as a chemically induced means to shut down emotional pain and thereby abort the natural process of exploring one’s pain, learning life lessons and growing to maturity. Finally, Dr. Levine counsels that working through depression with a good therapist can serve as a doorway to acquiring greater patience and compassion for oneself and others.

With anti-depressants and therapy it doesn’t have to be an either/or choice. Ideally someone with depression will make use of both modalities. Depending on a variety of circumstances (including variations in insurance coverage) you might end up extending your antidepressant use after short term therapy concludes or extending your therapy after a short course of antidepressant therapy picks up your mood. What I want to caution against it the over-reliance on drugs which is shown by just 20% of the respondents to the Consumer Reports survey indicating a preference for therapy.

Mood (whether one is happy and contented; bored, restless and hoping for change; or deeply sad, discouraged and depressed) is not just a matter of fortuitous brain chemistry. It is a reflection of one’s beliefs, behaviors and patterns of social interaction with other people and a barometer of whether one is living his life in a way which does (or does not) bring pleasure, engagement and meaning. You can help reverse depressed mood (to a point) with antidepressants at a certain financial cost and side-effect cost, but to change your long term satisfaction with your life requires therapy. If you’re so elated by the ease and convenience of taking anti-depressants as to think them the whole answer to the issue of depression, then you’re falling into a trap. Please don’t neglect therapy.

Click here to purchase The Upward Spiral: Getting Lawyers From Daily Misery To Lifetime Wellbeing by Harvey Hyman

Click here to purchase  audio downloads of  MCLE lectures by Harvey Hyman

REDUCE DEPRESSION BY BULKING UP YOUR ANTERIOR CINGULATE CORTEX WITH MEDITATION

Friday, June 4th, 2010

A cingulate is a curved bundle of nerves. The anterior cingulate cortex (ACC) is a collar shaped bundle of nerves that surrounds the corpus callosum within the frontal lobes of the human brain. The dorsal (top) portion of the ACC is involved with the cognitive function of monitoring task completion. The dorsal ACC helps us pay attention to where we are directing our attention and facilitates learning. It is stimulated by novelty and some neuroscientists believe it plays a role in error detection. The ventral (bottom) portion of the ACC has connections with many key brain areas. These are the amygdala (the brain’s fear alarm); the hypothalamus (which regulates appetite, sleep, and sex drive, and which also triggers the secretion of the stress hormones adrenalin and cortisol via the pituitary when the amygdala signals the approach of a threat); the nucleus accumbens (which uses dopamine to create the experiences of reward and pleasure); and the insula (the brain’s empathy center).

The ACC is situated between the frontal lobes (the seat of rational thought,  impulse control, self-image and self-esteem) and the subcortical limbic areas (the seat of our emotions, passions and drives). Working as a whole the ACC helps integrate thought with feeling as well as attention with motivation. The ventral ACC is extremely rich in serotonin transporters.

Although depression is a highly complex phenomenon with multiple causes, it appears that the ACC is involved. One study of depressed people using MRI found that depressed people had a smaller ACC than non-depressed volunteers. This study was published by Ramin S. Hastings of the New York Psychiatric Institute and colleagues in the March 2004 issue of Neuropharmacology.

Helen Mayberg. M.D. is a Board Certified neurologist who trained in neurology at  Columbia University and trained in nuclear medicine at Johns Hopkins. She has used PET scans to delineate brain activity in the neural circuits she believes play a role in causing depression. Dr. Mayberg has shown that the ventral ACC (also known as Broadmann’s Area 25) is hyperactive in depressed patients. She describes it as “a gate left open.” By that she means that negative, depressive emotions coming from the limbic area are allowed to flow freely across Area 25 in depressed patients and overwhelm the frontal lobes causing dark mood.

In February 2005 (just before she went to work at Emory University) Dr. Mayberg performed an experimental treatment on six seriously depressed patients at a clinic associated with Toronto University. She referred to these patients as being “terminally depressed,” since they had spent years in treatment with psychotherapy, anti-depressant medication and even electro-convulsive therapy, but had not gained any remission of their symptoms. Dr. Mayberg used a technique called DBS (deep brain stimulation) by inserting electrodes connected to a battery with adjustable current into Area 25 of their brains. All patients reported feeling better when the electric current pulsed into Area 25. Four of the six patients have achieved long term recovery from their depression by continuing to use DBS. Dr. Mayberg concluded that DBS had reduced and normalized the activity of their ventral ACC which effectively closed the gate between their negative emotions and their frontal lobes.

Dr. Mayberg continued her trials of DBS for treatment-refractory depressed patients. On February 19, 2009, the FDA approved the use of DBS for treatment of chronic, severe obsessive-compulsive disorder. Medtronic, Inc., the company which received the approval announced it would start a multi-center, randomized clinical trial of DBS for treatment-resistant depression.

If you’re a person who tried everything but failed to improve his depression without DBS, then wearing electrodes in your head and carrying around battery on your belt will be acceptable. On the other hand, what if you could significantly reduce your depressive symptoms through daily meditation? Wouldn’t that preferable?

There can be little doubt that forms of meditation devoted to increasing inner peace and tranquility or compassion and loving-kindness help relieve depression. One of the key factors in producing depression is high blood cortisol induced by chronic stress. Once you become depressed, the depressed state of mind keeps your cortisol level high because depressed people feel helpless, hopeless, and blameworthy, and they verbally attack themselves.

In September 1991 R. Sudsuang and colleagues in the Department of Physiology and Anatomy, Faculty of Medicine, Chulalongkorn University in Bangkok, Thailand, published a paper in Physiology & Behavior showing that 52 males aged 20-25 who  meditated regularly had significantly lower blood cortisol and blood pressure then 30 males in the same age group who did not meditate.

Zen meditation has been associated with decreased sensitivity to emotional and physical pain. In February 2010 Joshua A. Grant and colleagues in the Department of Physiology at the Universite de Montreal published a paper in a special issue of the APA Journal Emotion exploring the relationship of Zen meditation, cortical thickness and pain sensitivity. The researchers recruited 17 Zen meditators and 18 non-meditators. They measured pain sensitivity by applying a heated plate to the calf of the participants and followed by measuring brain volume with structural MRI. They determined that the Zen meditators were significantly less sensitive to pain and that consequent to years of meditation they had substantially thicker gray matter in their dorsal ACC, parts of their hippocampus and their insula – all areas involved in pain regulation.

Richard Davidson, Ph.D. is a neuroscientist who has been meditating every day since 1974 (while pursuing his Ph.D. at Harvard University) and has been a personal friend of the Dalai Lama since 1992. He is known all over the world for his work on how meditation physically changes the structure and function of our brains along with our emotional lives – in particular how meditation makes use of the neuroplasticity of our brains to make us more empathic, compassionate, and loving human beings. Dr. Davidson runs the Lab for Affective Neuroscience at the University of Wisconsin where he has done many groundbreaking studies using MRI on meditating Buddhist monks.

In one well known paper in 2003 Dr. Davidson teamed up with Jon Kabat-Zinn to study the effect of eight weeks of meditation on non-meditators. As reported in Volume 65 of Psychosomatic Medicine, the eight weeks led to increased subjective feelings of wellbeing, increased brain activation of the left frontal cortex (which is associated with feelings of wellbeing) and increased immune function with increased resistance to the flu virus.

Dr. Davidson has studied the ACC. In the July 28, 2000 issue of Science Dr. Davidson and colleagues used functional brain scans to analyze the brains of 500 people with difficulty regulating emotion including 41 murders. They found that murders had little or no activity in the orbito-frontal cortex (OFC) and ACC with heightened activity in their amygdala (which sounds the fear alarm in response to potential threats). The OFC is supposed to constrain violent impulses, while the ACC mediates between the OFC and the amygdala and is supposed to help resolve decisions about how to respond to threat. These individuals became overwhelmed by the neural messages of threat/fear/defend from the amygdala, because their OFC and ACC were not functioning normally.

Based on the work of Dr. Mayberg and Dr. Davidson it appears that abnormalities in ACC function (hyperactivity or no activity) are associated with depression or violence. This makes sense since depression is a form of violence directed at the self. Further violence and depression are both mental states of great agitation, unhappiness and suffering associated with inability to regulate one’s emotions.

Meditation can thicken and strengthen your ACC, and help you regulate your emotions and decrease your sensitivity to emotional and physical pain. It can make you less reactive and more even-keeled. If you haven’t  tried it, start today. Begin exploring various forms of meditation taught in community and find one that works for you.

Click here to purchase The Upward Spiral: Getting Lawyers From Daily Misery To Lifetime Wellbeing by Harvey Hyman

Click here to purchase  audio downloads of  MCLE lectures by Harvey Hyman

THE RELATIONSHIP BETWEEN SMOKING AND DEPRESSION

Thursday, June 3rd, 2010

The human brain is filled with nicotinic acetylcholine receptors which are found primarily in the thalamus, basal ganglia, cerebral cortex, hippocampus, and cerebellum. There are twelve subtypes of these receptors. These receptors existed in the human brain for acetylcholine long before humans figured out how to cure and smoke tobacco leaves. The neurotransmitter acetylcholine, nicotine from cigarette smoking and stop-smoking drugs like Mecamylamine and Varenicline each activate these receptors. More depressed people smoke than non-depressed people. Does this mean that smoking causes depression or that smoking relieves depressive symptoms and that smoking is a form of self-medication?

Joseph Boden et al. of the Department of Psychological Medicine at Otago University in New Zealand published research on the prevalence of smoking in depressed vs. non-depressed people in the June 2010 issue of the British Journal of Psychiatry. They surveyed the smoking habits and depressive symptoms of 1,000 people at ages 18, 21 and 25. They concluded that smoking doubles the risk of experiencing depression. Was this conclusion correct?

Ingrid Bacher, Ph.D. is a psychiatric researcher at the University of Toronto. She and her colleagues published a review paper in Volume 17, Issue 1, of Primary Psychiatry, showing that people with neuropsychiatric disorders are five times more likely to smoke than normals. Each group of people with a neuropsychiatric disorder (be it schizophrenia, major depression, ADHD, autism, Alzheimer’s disease or Parkinson’s disease) benefits from smoking for different reasons. For instance schizophrenics can think more clearly and depressed people become more responsive to pleasure.

Dr. Bacher points out that the nicotine from cigarette smoking has something for everyone in these groups of sufferers, since activation of the nicotinic acetylcholine receptors by nicotine can stimulate the release of feel-good substances including dopamine, serotonin, norepinephrine, GABA (an inhibitory neurotransmitter which calms the brain) and opioid peptides (which decrease pain and increase euphoria). The problem with smoking is that kills people by causing lung and other cancers.

With regard major depressive disorder Dr. Bacher points to research showing that some cases are due to excessive production of acetylcholine. She concludes that depressed people who smoke probably experience a reduction in symptoms because nicotine binding to nicotinic acetylcholine receptors stimulates increased production of serotonin, and because it also reduces and normalizes the production of acetylcholine. Her own work with rodents has shown that the stop-smoking drug Mecamylamine has an anti-depressive effect because it blocks the production of excess acetylcholine. Mecamylamine was originally developed as an anti-hypertension drug, but it was found to help some people stop smoking and it is used more today as a stop-smoking drug.

Dr. Bacher is not endorsing smoking as a cure for depression. Far from it. She wants to find a way to help people with depression break the habit and find another way to get relief. She believes that smoking is an attempt by people with neuropsychiatric disorders (including major depressive disorder) to reduce the symptoms which make them suffer, and that the use of medications like Mecamylamine could help depressed people break their addiction to smoking while helping to relieve their underlying symptoms.

This is a complex area. New research is coming out all the time and the research will change what we know. However, based on what Dr. Bacher discussed in her paper,  if you are seriously depressed and you smoke, it may be more beneficial to quit using a stop smoking drug which regulates the nicotinic acetylcholine receptors (and reduces acetylcholine transmission) than to go “cold turkey,” which will stop nicotine consumption but leave excess acetylcholine in your system. This is something to discuss carefully with your physician or your treating psychiatrist if you have one.

Click here to purchase The Upward Spiral: Getting Lawyers From Daily Misery To Lifetime Wellbeing by Harvey Hyman

Click here to purchase  audio downloads of  MCLE lectures by Harvey Hyman

THE NEUROGENESIS THEORY OF DEPRESSION

Monday, May 31st, 2010
The older theory of depression was that it resulted from a deficiency of neurotransmitters like serotonin, dopamine or epinephrine. The monkey wrench in the spokes of this theory was that taking an anti-depressant immediately increased the supply of the deficient neurotransmitter in brain synapses but it took several weeks to notice an improvement in mood. If depression was caused solely by an under supply of a neurotransmitter like serotonin, and Prozac increases the brain’s stock of serotonin right away, then why wouldn’t a depressed patient taking Prozac feel better right away?
About a decade ago neuroscientists established that new brain cells are born in adults in an area of the brain called the hippocampus. This birthing process was called neurogenesis (neuro for neurons and genesis for birth of). They also discovered that depressed patients have much lower rates of neurogenesis than normals in their hippocampus and that their hippocampi are smaller, on average about 20% smaller than that of normals. Is reduced neurogenesis the cause of depression, a result of depression, or both?
Depression is initially a response to chronic stress, but depression stresses the brain because being in a state of chronic fight-flight keeps cortisol levels high and cortisol kills brain cells in the hippocampus. Neurophysiologists like Robert Sapolsky, Ph.D. showed that one reason for the difference in hippocampal size between depressed and non-depressed individuals is that high cortisol levels shrinks their hippocampi.
Over the past decade a number of neuroscientists have shown that antidepressants stimulate neurogenesis in the adult human hippocampus, which means they increase the rate of production of new neurons there. Based on this observation, some neuroscientists have hypothesized that antidepressants improve depression by stimulating neurogenesis there. The theory goes that antidepressants take a few weeks to work because time is needed to birth enough new brain cells to alter mood. Some have questioned the theory on the grounds that the hippocampus facilitates memory and learning, but has little to do with mood regulation.
The theory is being tested on mice to see if anti-depressants had an immediate or a delayed effect in reversing depressed behavior. A mouse is considered to be depressed if he falls quickly off of a stick instead of holding on with his tail or quickly resorts to floating in a beaker of water instead of trying to vigorously swim his way out. If antidepressants work on such a mouse, he will hold onto the stick upside down with his tail for a much longer time and will swim in the beaker of water for a much longer time.
Mice, like humans, have a protein called CREB (cAMP response element-binding protein) which binds to DNA sequences, affects gene expression and affects the rate of neurogenesis. Scientists created a strain of CREB deficient mice which tend to be anxious. They observed that the CREB deficient mice had a higher rate of neurogenesis in their hippocampi than normal mice but had the same amount of serotonin as normal mice.  When CREB deficient mice were given  the tail suspension test and forced swim test they did well showing they were not depressed. Then the researchers depleted the amount of serotonin in their brains. This not only caused the CREB deficient mice to flunk the tail suspension and forced swim tests (showing them to be depressed), but they showed reduced neurogenesis in their hippocampi. Giving the CREB deficient mice an antidepressant enabled them to perform normally on the two tests right away without delay.
In second test the scientists gave normal mice and CREB deficient mice Reeses pieces. Both gobbled them up right away in a familiar environment, but when placed in a new environment (which induced stress) they took time to feel comfortable in the new environment before they would eat their beloved Reeses pieces. When the normal mice were given antidepressants they immediately ate the Reeses pieces in the new environment but the CREB deficient mice needed a few weeks.
This research was published in 2007 by Tamar L.Gur and colleagues in the Departments of Pharmacology and Psychiatry at the University of Pennsylvania School of Medicine in the Journal. Their article is titled cAMP Response Element-Binding Protein Deficiency Allows for Increased Neurogenesis and a Rapid Onset of Antidepressant Response.
This publication and others like it leave the field in a state of confusion. We do know that antidepressant medication increases neurogenesis in the hippocampus, but we still can’t explain why extra new brain cells there would improve mood, why there is a delay in beneficial effects or all antidepressant users and why less than half of depressed people respond well to antidepressants. The research will continue, but for now the idea that neurogenesis explains why antidepressants work in humans is just an intriguing possibility. Some researchers have predicted it will one day explain why some people benefit but will not become a universal explanation.
The older theory of depression was that it resulted from a deficiency of neurotransmitters like serotonin, dopamine or epinephrine. The monkey wrench in the spokes of this theory was that taking an anti-depressant immediately increased the supply of the deficient neurotransmitter in brain synapses but it took several weeks to notice an improvement in mood. If depression was caused solely by an under supply of a neurotransmitter like serotonin, and Prozac increases the brain’s stock of serotonin right away, then why wouldn’t a depressed patient taking Prozac feel better right away?
About a decade ago neuroscientists established that new brain cells are born in adults in an area of the brain called the hippocampus. This birthing process was called neurogenesis (neuro for neurons and genesis for birth of). They also discovered that depressed patients have much lower rates of neurogenesis than normals in their hippocampus and that their hippocampi are smaller, on average about 20% smaller than that of normals. Is reduced neurogenesis the cause of depression, a result of depression, or both?
Depression is initially a response to chronic stress, but depression stresses the brain because being in a state of chronic fight-flight keeps cortisol levels high and cortisol kills brain cells in the hippocampus. Neurophysiologists like Robert Sapolsky, Ph.D. showed that one reason for the difference in hippocampal size between depressed and non-depressed individuals is that high cortisol levels shrinks their hippocampi.
Over the past decade a number of neuroscientists have shown that antidepressants stimulate neurogenesis in the adult human hippocampus, which means they increase the rate of production of new neurons there. Based on this observation, some neuroscientists have hypothesized that antidepressants improve depression by stimulating neurogenesis there. The theory goes that antidepressants take a few weeks to work because time is needed to birth enough new brain cells to alter mood. Some have questioned the theory on the grounds that the hippocampus facilitates memory and learning, but has little to do with mood regulation.
The theory is being tested on mice to see if anti-depressants had an immediate or a delayed effect in reversing depressed behavior. A mouse is considered to be depressed if he falls quickly off of a stick instead of holding on with his tail or quickly resorts to floating in a beaker of water instead of trying to vigorously swim his way out. If antidepressants work on such a mouse, he will hold onto the stick upside down with his tail for a much longer time and will swim in the beaker of water for a much longer time.
Mice, like humans, have a protein called CREB (cAMP response element-binding protein) which binds to DNA sequences, affects gene expression and affects the rate of neurogenesis. Scientists created a strain of CREB deficient mice which tend to be anxious. They observed that the CREB deficient mice had a higher rate of neurogenesis in their hippocampi than normal mice but had the same amount of serotonin as normal mice.  When CREB deficient mice were given  the tail suspension test and forced swim test they did well showing they were not depressed. Then the researchers depleted the amount of serotonin in their brains. This not only caused the CREB deficient mice to flunk the tail suspension and forced swim tests (showing them to be depressed), but they showed reduced neurogenesis in their hippocampi. Giving the CREB deficient mice an antidepressant enabled them to perform normally on the two tests right away without delay.
In second test the scientists gave normal mice and CREB deficient mice Reeses pieces. Both gobbled them up right away in a familiar environment, but when placed in a new environment (which induced stress) they took time to feel comfortable in the new environment before they would eat their beloved Reeses pieces. When the normal mice were given antidepressants they immediately ate the Reeses pieces in the new environment but the CREB deficient mice needed a few weeks.
This research was published in 2007 by Tamar L.Gur and colleagues in the Departments of Pharmacology and Psychiatry at the University of Pennsylvania School of Medicine in the Journal. Their article is titled cAMP Response Element-Binding Protein Deficiency Allows for Increased Neurogenesis and a Rapid Onset of Antidepressant Response.
This publication and others like it leave the field in a state of confusion. We do know that antidepressant medication increases neurogenesis in the hippocampus, but we still can’t explain why extra new brain cells there would improve mood, why there is a delay in beneficial effects or all antidepressant users and why less than half of depressed people respond well to antidepressants. The research will continue, but for now the idea that neurogenesis explains why antidepressants work in humans is just an intriguing possibility. Some researchers have predicted it will one day explain why some people benefit but will not become a universal explanation.

Click here to purchase The Upward Spiral: Getting Lawyers From Daily Misery To Lifetime Wellbeing by Harvey Hyman

Click here to purchase  audio downloads of  MCLE lectures by Harvey Hyman